Monroe Anne K, Levy Matthew E, Greenberg Alan E, Keruly Jeanne C, Moore Richard D, Horberg Michael A, Kulie Paige, Mohanraj Bernadine S, Kumar Princy N, Castel Amanda D
The George Washington University, Washington, DC, USA.
Westat, Rockville, Maryland, USA.
Open Forum Infect Dis. 2021 Jul 27;8(8):ofab338. doi: 10.1093/ofid/ofab338. eCollection 2021 Aug.
Integrase inhibitors (INSTIs) are recommended by expert panels as initial therapy for people with HIV. Because there can be disparities in prescribing and uptake of novel and/or recommended therapies, this analysis assessed potential INSTI prescribing disparities using a combined data set from the Johns Hopkins HIV Clinical Cohort and the DC Cohort. We performed multivariable logistic regression to identify factors associated with ever being prescribed an INSTI. Disparities were noted, including clinic location, age, and being transgender. Identifying disparities may allow clinicians to focus their attention on these individuals and ensure that therapy decisions are grounded in valid clinical reasons.
整合酶抑制剂（INSTIs）被专家小组推荐作为HIV感染者的初始治疗方案。由于新型和/或推荐疗法在处方和使用方面可能存在差异，本分析使用约翰·霍普金斯HIV临床队列和华盛顿特区队列的合并数据集评估了潜在的整合酶抑制剂处方差异。我们进行了多变量逻辑回归，以确定与曾接受整合酶抑制剂处方相关的因素。发现了一些差异，包括诊所位置、年龄和跨性别身份。识别这些差异可能使临床医生将注意力集中在这些个体身上，并确保治疗决策基于有效的临床理由。
